Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

類似資料

• Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease
  著者:: Meijer, Esther, 等
  出版事項: (2013)
• Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial
  著者:: Chrispijn, Melissa, 等
  出版事項: (2011)
• A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease
  著者:: Casteleijn, Niek F., 等
  出版事項: (2014)
• Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial
  著者:: Meijer, Esther, 等
  出版事項: (2018)
• Impact of liver volume on polycystic liver disease-related symptoms and quality of life
  著者:: Neijenhuis, Myrte K, 等
  出版事項: (2017)